A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
An estimated 150 babies were born in Gaza per day since the start of the conflict. A pediatric doctor at the Emirati Hospital in Rafah, stated the number of premature babies born in Gaza had risen sharply. Newborn babies receiving specialized care in Israel and the West Bank while their mothers were trapped in Gaza. Oxfam stated newborn babies were dying from preventable diseases such as infection, hypothermia, diarrhea, and dehydration. By mid-December, parents were struggling to feed newborn babies, as mothers had insufficient nutrition to breastfeed. Newborn babies born during the conflict died in airstrikes, though some were rescued from the rubble. A UNOCHA representative stated she had met a woman forced to give birth in the street, and that the baby had died. One woman reported being unable to bathe her newborns more than ten days after their birth, due to the lack of clean water. Mothers reported extreme difficulty locating or affording milk and diapers for their newborns. In December 2023, an Israeli shell struck the largest fertility clinic in Gaza; the explosion knocked the lids off five liquid nitrogen tanks, causing temperature within the tanks to rise and destroying more than 4,000 embryos and 1,000 specimens of unfertilized eggs and sperm. According to Bahaeldeen Ghalayini, the obstetrician and gynaecologist who founded the clinic, the corner of the building was hit by a single shell, destroying the ground floor embryology lab; he does not know whether the strike was intentional or not.
The hydroxylation of estradiol is one of the major routes of metabolism of the estrogen steroid hormone estradiol. It is hydroxylated into the catechol estrogens 2-hydroxyestradiol and 4-hydroxyestradiol and into estriol (16α-hydroxyestradiol), reactions which are catalyzed by cytochrome P450 enzymes predominantly in the liver, but also in various other tissues.
=== Companies === To translate his discoveries into therapeutics, Verdine has founded or co-founded numerous public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron. He also founded the private company Gloucester Pharmaceuticals, which was acquired by Celgene in 2009. His companies share the mission of developing molecules intended to target “hard-to-drug” endogenous targets that have remained out of reach of modern cell-penetration technologies.
Sources: en.wikipedia.org
Virginia Minnich (1910–1996) was an American molecular biologist and hematology researcher known for discovering hemoglobin E, an abnormal form of hemoglobin that can cause blood disorders, and for working out the glutathione synthesis pathway. She was a noted blood morphologist and teacher and helped set up hematology laboratories around the world. She was the first person without a PhD or MD to be appointed a Professor of Medicine at Washington University School of Medicine.
Scytalidocarboxyl peptidase B, also known as Scytalidoglutamic peptidase and Scytalidopepsin B (EC 3.4.23.32, obsolete names include Scytalidium aspartic proteinase B, Ganoderma lucidum carboxyl proteinase, Ganoderma lucidum aspartic proteinase, Scytalidium lignicolum aspartic proteinase B, SLB) is a proteolytic enzyme. It was previously thought to be an aspartic protease, but determination of its molecular structure showed it to belong a novel group of proteases, glutamic protease. The protease has a unique structure and a novel catalytic dyad (E136 and Q53) in its active site. The active-site residues, glutamic acid (E) and glutamine (Q), was used to coin the name of the family of proteases; eqolisins, to which Scytalidoglutamic peptidase B belongs. This enzyme catalyses the following chemical reaction
In his introduction, he praised Chomsky as "a very vocal and important voice in the wilderness of intellectual life in America" and said that he was "delighted to welcome a person who I think we're all very proud of". Sanders hosted and produced a public-access television program, Bernie Speaks with the Community, from 1986 to 1988. He collaborated with 30 Vermont musicians to record a folk album, We Shall Overcome, in 1987. That same year, US News & World Report ranked Sanders one of America's best mayors. As of 2013, Burlington was regarded as one of the most livable cities in the United States. During a trip to the Soviet Union in 1988, Sanders interviewed the mayor of Burlington's sister city Yaroslavl about housing and health care issues in the two cities. When Sanders left office in 1989, Bouricius, a member of the Burlington city council, said that Sanders had "changed the entire nature of politics in Burlington and also in the state of Vermont".
Sources: en.wikipedia.org
[peptide]-(2S)-2-hydroxyglycine = [peptide]-amide + glyoxylate This enzyme belongs to the family of lyases, specifically amidine lyases. The systematic name of this enzyme class is [peptide]-(2S)-2-hydroxyglycine peptidyl-amide-lyase (glyoxylate-forming). Other names in common use include α-hydroxyglycine amidating dealkylase, peptidyl-α-hydroxyglycine α-amidating lyase, HGAD, PGL, PAL, and peptidylamidoglycolate peptidylamide-lyase.
Bacillus virus φ29 (bacteriophage φ29) is a double-stranded DNA (dsDNA) bacteriophage with a prolate icosahedral head and a short tail that belongs to the genus Salasvirus, order Caudovirales, and family Salasmaviridae. They are in the same order as phages PZA, φ15, BS32, B103, M2Y (M2), Nf, and GA-1. First discovered in 1965, the φ29 phage is the smallest Bacillus phage isolated to date and is among the smallest known dsDNA phages. φ29 has a unique DNA packaging motor structure that employs prohead packaging RNA (pRNA) to guide the translocation of the phage genome during replication. This novel structure system has inspired ongoing research in nanotechnology, drug delivery, and therapeutics. In nature, the φ29 phage infects Bacillus subtilis, a species of gram-positive, endospore-forming bacteria that is found in soil, as well as the gastrointestinal tracts of various marine and terrestrial organisms, including human beings.
The Magnetic Levitation Method (MLM) is a technique for growing 3D cell cultures. In this approach, cells are treated with magnetic nanoparticles and exposed to spatially varying magnetic fields produced by neodymium magnetic drivers. The process causes cells to levitate to the air-liquid interface within a standard petri dish. The magnetic nanoparticle assemblies consist of magnetic iron oxide nanoparticles, gold nanoparticles, and cell-adhesive peptide sequences. This method can be applied to cultures with five hundred to millions of cells and is adaptable for use in single-dish systems as well as high-throughput, low-volume systems. Magnetized cells can also be used as building blocks for magnetic 3D bioprinting.
==== Notable incidents ==== The state of Florida used midazolam to execute William Frederick Happ in October 2013. The state of Ohio used midazolam in the execution of Dennis McGuire in January 2014; he was heavily anesthetized and unconscious within 4 minutes of starting the administration of midazolam and 20 more minutes after that point before he was declared medically dead. Controversy arose after he was observed gasping and appeared to choke during that time according to reporters who were allowed to be present, leading to questions about the dosing and timing of the drug administration, as well as the choice of drugs. The usage of midazolam in executions became controversial after condemned inmate Clayton Lockett apparently regained consciousness and started speaking midway through his 2014 execution when the state of Oklahoma attempted to execute him with an untested three-drug lethal injection combination including 100 mg of midazolam. Prison officials reportedly discussed taking him to a hospital before he was pronounced dead of a heart attack 40 minutes after the execution began. An observing doctor stated that Lockett's vein had ruptured. It is not clear whether his death was caused by one or more of the drugs or by a problem in the administration procedure, nor is it clear what quantities of vecuronium bromide and potassium chloride were released to his system before the execution was cancelled.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.